According to the latest report by IMARC Group, titled “Viscosupplementation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global viscosupplementation market size reached US$ 4.1 Billion in 2022. Viscosupplementation is a medical procedure commonly used to provide relief to individuals suffering from osteoarthritis. It involves the injection of a gel-like substance directly into the affected joint. The injected fluid acts as a lubricant, reducing friction between the bones and allowing for smooth movement. The aim of viscosupplementation is to supplement the diminished levels of hyaluronic acid in the affected joint, thereby improving joint mobility, reducing pain, and potentially delaying the need for more invasive treatments, such as joint replacement surgery. Additionally, it restores the rheological properties of the synovial fluids, resulting in mechanical, analgesic, anti-inflammatory, and chondroprotective benefits. As a result, it is widely used for the treatment of osteoarthritis in the hip, knee, and hand.
Global Viscosupplementation Market Trends:
The global market is majorly driven by the increasing prevalence of osteoarthritis among the masses. Along with this, with the growing elderly population, there is a greater need for treatments that can alleviate joint pain and improve mobility, thus propelling the demand for viscosupplementation. Moreover, the increased awareness about treatment options and patient education regarding the benefits of viscosupplementation is significantly supporting the market. Besides, changing lifestyles, including sedentary habits and participation in sports activities, are also strengthening the market as these injuries lead to the development of osteoarthritis, further impelling the demand for viscosupplementation as a treatment option. Apart from this, the emergence of ambulatory surgical centers (ACS) that offer intensive treatment to resolve surgical and non-surgical problems in various body parts, such as joints, ligaments, muscles, spine, and nerves, is impacting the market favorably. Furthermore, several major companies are heavily investing in developing new formulations with enhanced properties, longer-lasting effects, and improved patient outcomes, thus providing a boost to the market. Additionally, ongoing technological advancements in delivery systems, such as pre-filled syringes and autoinjectors, are acting as another growth-inducing factor. Looking forward, the market value is projected to reach US$ 6.8 Billion by 2028, expanding at a CAGR of 8.5% during 2023-2028.
- Based on the type, the market has been segmented into single, three and five injection. Currently, single injection represents the largest market segment.
- On the basis of the age group, the market has been divided into adults and geriatric. Presently, geriatrics accounts for the largest market share.
- Based on the distribution channel, the market has been bifurcated into hospital, retail, and online pharmacies. Among these, hospital pharmacies exhibit a clear dominance in the market.
- On the basis of the application, the market has been categorized into knee osteoarthritis, hip osteoarthritis and hand osteoarthritis, and others. Presently, knee osteoarthritis accounts for the largest market share.
- Based on the end use, the market has been segmented into hospitals, orthopedic clinics, and others. Among these, orthopedic clinics exhibit a clear dominance in the market.
- Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Among these, North America holds the leading position in the market.
- The competitive landscape of the market has also been examined, with some of the key players being Anika Therapeutics Inc., Aptissen S.A., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici S.p.A., Johnson & Johnson, LG Chem Ltd., OrthogenRx Inc. (Avanos Medical Inc.), Sanofi S.A., Seikagaku Corporation, Virchow Biotech Private Limited, Zimmer Biomet, and Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited).
|Base Year of the Analysis
||Single Injection, Three Injection, Five Injection
|Age Groups Covered
|Distribution Channels Covered
||Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
||Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Others
|End Uses Covered
||Hospitals, Orthopedic Clinics, Others
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Anika Therapeutics Inc., Aptissen S.A., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici S.p.A., Johnson & Johnson, LG Chem Ltd., OrthogenRx Inc. (Avanos Medical Inc.), Sanofi S.A., Seikagaku Corporation, Virchow Biotech Private Limited, Zimmer Biomet, Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited), etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800